Literature DB >> 15020279

High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.

Roberto Cairoli, Giovanni Grillo, Alessandra Tedeschi, Giovanna D'Avanzo, Paola Marenco, Enrica Morra.   

Abstract

We report a high incidence of neutropenia in patients treated with rituximab prior to and following autologous stem cell transplantation (ASCT). Fourteen patients with follicular or mantle-cell lymphoma were treated with high dose (HD) therapy followed by an in vivo-purged autologous graft.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15020279

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  8 in total

Review 1.  The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.

Authors:  Elizabeth Naparstek
Journal:  Curr Hematol Malig Rep       Date:  2006-12       Impact factor: 3.952

Review 2.  A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug.

Authors:  David Rey Arpon; Maher K Gandhi; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

3.  Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.

Authors:  Wen-Kai Weng; Robert S Negrin; Philip Lavori; Sandra J Horning
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

4.  Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.

Authors:  Daniel Tesfa; Tobias Gelius; Birgitta Sander; Eva Kimby; Bengt Fadeel; Jan Palmblad; Hans Hägglund
Journal:  Med Oncol       Date:  2008-02-16       Impact factor: 3.064

Review 5.  Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.

Authors:  William E Monaco; Jonathan D Jones; William F C Rigby
Journal:  Clin Rheumatol       Date:  2016-05-21       Impact factor: 2.980

6.  Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.

Authors:  Paul M Barr; Pingfu Fu; Hillard M Lazarus; Nancy Horvath; Stanton L Gerson; Omer N Koc; Nizar J Bahlis; Michael R Snell; Afshin Dowlati; Brenda W Cooper
Journal:  Br J Haematol       Date:  2009-06-29       Impact factor: 6.998

7.  Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.

Authors:  Sofia Ajeganova; Daniel Tesfa; Hans Hägglund; Bengt Fadeel; Inger Vedin; Anna Linda Zignego; Jan Palmblad
Journal:  Arthritis Res Ther       Date:  2017-03-07       Impact factor: 5.156

8.  Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort.

Authors:  Chace Mitchell; Courtney B Crayne; Randy Q Cron
Journal:  ACR Open Rheumatol       Date:  2019-08-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.